Search Results - "Janja, Ocvirk"

Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial by Cunningham, David, Prof, Lang, Istvan, MD, Marcuello, Eugenio, MD, Lorusso, Vito, MD, Ocvirk, Janja, MD, Shin, Dong Bok, MD, Jonker, Derek, MD, Osborne, Stuart, MSc, Andre, Niko, MD, Waterkamp, Daniel, MD, Saunders, Mark P, MD

“…Summary Background Elderly patients are often under-represented in clinical trials of metastatic colorectal cancer. We aimed to assess the efficacy and safety…”
Get full text

The five-year KRAS, NRAS and BRAF analysis results and treatment patterns in daily clinical practice in Slovenia in 1st line treatment of metastatic colorectal (mCRC) patients with RAS wild-type tumour (wtRAS) – a real- life data report 2013–2018 by Mesti, Tanja, Rebersek, Martina, Ocvirk, Janja

“…We preformed a Phase IV non-interventional study to assess KRAS, NRAS and BRAF status in metastatic colorectal cancer (mCRC) patients suitable for 1st line…”
Get full text

Malignant gliomas: old and new systemic treatment approaches by Mesti, Tanja, Ocvirk, Janja

“…Malignant (high-grade) gliomas are rapidly progressive brain tumours with very high morbidity and mortality. Until recently, treatment options for patients…”
Get full text

Prognostic factors for overall survival and safety of trans-arterial chemoembolization (TACE) with irinotecan-loaded drug-eluting beads (DEBIRI) in patients with colorectal liver metastases by Sljivic, Maja, Sever, Masa, Ocvirk, Janja, Mesti, Tanja, Brecelj, Erik, Popovic, Peter

“…Transarterial chemoembolisation with irinotecan-loaded drug-eluting beads (DEBIRI TACE) can be considered in patients with unresectable colorectal cancer liver…”
Get full text

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors by Mesti, Tanja, Grašič Kuhar, Cvetka, Ocvirk, Janja

“…A high proportion of metastatic melanoma patients do not respond to immune checkpoint inhibitors (ICI), and until now, no validated biomarkers for response and…”
Get full text

Ocular changes in metastatic melanoma patients treated with MEK inhibitor cobimetinib and BRAF inhibitor vemurafenib by Gavric, Ana Ursula, Ocvirk, Janja, Mekjavic, Polona Jaki

“…Mitogen-activated protein kinase kinase (MEK) inhibitor cobimetinib and V-raf murine sarcoma viral oncogene homolog B1 (BRAF) inhibitor vemurafenib have…”
Get full text

Capecitabine plus Irinotecan (XELIRI regimen) compared to 5-FU/LV plus Irinotecan (FOLFIRI regimen) as neoadjuvant treatment for patients with unresectable liver-only metastases of metastatic colorectal cancer: a randomised prospective phase II trial by Skof, Erik, Rebersek, Martina, Hlebanja, Zvezdana, Ocvirk, Janja

“…Phase II studies have shown that the combination of capecitabine and irinotecan (the XELIRI regimen) is active in metastatic colorectal cancer (MCRC). There…”
Get full text

Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients by Rebersek, Martina, Mesti, Tanja, Boc, Marko, Ocvirk, Janja

“…Background Histological parameters of primary tumour and nodal metastases are prognostic factors for survival of operable colorectal (CRC) patients, but not…”
Get full text

Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study by Velenik, Vaneja, Ocvirk, Janja, Music, Maja, Bracko, Matej, Anderluh, Franc, Oblak, Irena, Edhemovic, Ibrahim, Brecelj, Erik, Kropivnik, Mateja, Omejc, Mirko

“…Preoperative capecitabine-based chemoradiation is a standard treatment for locally advanced rectal cancer (LARC). Here, we explored the safety and efficacy of…”
Get full text

Metabolic impact of anti-angiogenic agents on U87 glioma cells by Mesti, Tanja, Savarin, Philippe, Triba, Mohamed N, Le Moyec, Laurence, Ocvirk, Janja, Banissi, Claire, Carpentier, Antoine F

“…Glioma cells not only secrete high levels of vascular endothelial growth factor (VEGF) but also express VEGF receptors (VEGFR), supporting the existence of an…”
Get full text

Adverse events during immunotherapy in Slovenian patients with metastatic melanoma reveal a positive correlation with better treatment outcomes by Mesti, Tanja, Ceplak Mencin, Vid, Mileva Boshkoska, Biljana, Ocvirk, Janja

“…Immunotherapy with CTLA-4 inhibitors and PD1 checkpoint inhibitors has initiated a breakthrough in the treatment and prognosis of patients with metastatic…”
Get full text

Basophil Activation Test Predicts Cetuximab Anaphylaxis Severity in Alpha-Gal IgE-Positive Patients by Kopač, Peter, Koren, Ana, Bidovec-Stojkovič, Urška, Košnik, Mitja, Dejanović, Luka, Mesti, Tanja, Strojan, Primož, Korošec, Peter, Ocvirk, Janja

“…Upon first exposure to cetuximab, hypersensitivity reactions can occur. We aimed to assess the utility of the basophil activation test (BAT) to alpha-gal and…”
Get full text

Retrospective analysis of treatment-naive Slovenian patients with metastatic melanoma treated with pembrolizumab – real-world experience by Hribernik, Nezka, Boc, Marko, Ocvirk, Janja, Knez-Arbeiter, Jasna, Mesti, Tanja, Ignjatovic, Marija, Rebersek, Martina

“…Background Based on recent data from clinical trials, the immune checkpoint inhibitor pembrolizumab prolongs survival and has a good toxicity profile in…”
Get full text

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial by Ocvirk, Janja, Brodowicz, Thomas, Wrba, Fritz, Ciuleanu, Tudor E, Kurteva, Galina, Beslija, Semir, Koza, Ivan, Pápai, Zsuzsanna, Messinger, Diethelm, Yilmaz, Ugur, Faluhelyi, Zsolt, Yalcin, Suayib, Papamichael, Demetris, Wenczl, Miklós, Mrsic-Krmpotic, Zrinka, Shacham-Shmueli, Einat, Vrbanec, Damir, Esser, Regina, Scheithauer, Werner, Zielinski, Christoph C

“…To investigate efficacy and safety of cetuximab combined with two chemotherapy regimens in patients with unresectable metastatic colorectal cancer (mCRC)…”
Get full text

Impact of perioperative treatment on survival of resectable gastric cancer patients after D2 lymphadenectomy: a single European centre propensity score matching analysis by Jagric, Tomaz, Ilijevec, Bojan, Velenik, Vaneja, Ocvirk, Janja, Potrc, Stojan

“…Background To determine the effects of perioperative treatment of gastric cancer patients, we conducted an analysis with propensity score matched patient…”
Get full text

Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells by Mesti, Tanja, Bouchemal, Nadia, Banissi, Claire, Triba, Mohamed N., Marbeuf-Gueye, Carole, Cemazar, Maja, Moyec, Laurence Le, Carpentier, Antoine F., Savarin, Philippe, Ocvirk, Janja

“…Background Malignant gliomas are rapidly growing tumours that extensively invade the brain and have bad prognosis. Our study was performed to assess the…”
Get full text

The Prognostic and Predictive Value of Human Gastrointestinal Microbiome and Exosomal mRNA Expression of PD-L1 and IFNγ for Immune Checkpoint Inhibitors Response in Metastatic Melanoma Patients: PROTOCOL TRIAL by Erman, Ana, Ignjatović, Marija, Leskovšek, Katja, Miceska, Simona, Lampreht Tratar, Urša, Bošnjak, Maša, Kloboves Prevodnik, Veronika, Čemažar, Maja, Kandolf Sekulovič, Lidija, Avguštin, Gorazd, Ocvirk, Janja, Mesti, Tanja

“…Immunotherapy has been successful in treating advanced melanoma, but a large proportion of patients do not respond to the treatment with immune checkpoint…”
Get full text

Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma by Moltara, Maja Ebert, Novakovic, Srdjan, Boc, Marko, Bucic, Marina, Rebersek, Martina, Zadnik, Vesna, Ocvirk, Janja

“…Background BRAF, NRAS and c-KIT mutations are characteristics of tumour tissues that influence on treatment decisions in metastatic melanoma patients. Mutation…”
Get full text

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience by Mesti, Tanja, Ebert Moltara, Maja, Boc, Marko, Rebersek, Martina, Ocvirk, Janja

“…Background. Treatment options of recurrent malignant gliomas are very limited and with a poor survival benefit. The results from phase II trials suggest that…”
Get full text

Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score by Gaiser, Maria R., Lorenzen, Sylvie, Merx, Kirsten, Trojan, Jörg, Ocvirk, Janja, Ettrich, Thomas J., Al‐Batran, Salah‐Eddin, Schulz, Holger, Homann, Nils, Feustel, Hans‐Peter, Schatz, Michael, Kripp, Melanie, Schulte, Nadine, Heeger, Steffen, Vlassak, Soetkin, Koch, Winfried, Hofheinz, Ralf‐Dieter

“…Acne‐like skin reactions frequently occur in patients undergoing treatment with drugs inhibiting the epidermal growth factor receptor. Recently, the effects of…”
Get full text